NEW YORK, September 22, 2015 /PRNewswire/ --
Equity Research Institute has initiated coverage on the
following equities: Baxalta Inc. (NYSE: BXLT), Opko Health Inc.
(NYSE: OPK), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI),
Arrowhead Research Corporation (NASDAQ: ARWR), and Oncothyreon Inc.
(NASDAQ: ONTY). Free research report on Baxalta can be accessed at
https://www.erionline.net/BXLT.pdf On Monday, September 21, 2015, the NASDAQ Composite
ended at 4,828.96, up 0.04%, the Dow Jones Industrial Average
advanced 0.77%, to finish the day at 16,510.19, and the S&P 500
closed at 1,966.97, up 0.46%. The gains were broad based as seven
out of nine sectors ended the session in positive. Register for
your complimentary reports at the links given below.
Baxalta Inc.'s stock lost 2.25%, to close the day at
$36.07. The stock recorded a trading
volume of 2.53 million shares, much below its three months average
volume of 5.24 million shares. Over the previous three months and
since the start of this year, Baxalta Inc.'s shares have gained
13.12% and 7.89%, respectively. However, the stock has lost 8.89%
in the last one month. The company's shares are trading 2.96% and
5.32% above their 50-day and 200-day moving averages, respectively.
Additionally, Baxalta Inc. traded at a PE ratio of 22.13 and has a
Relative Strength Index (RSI) of 52.10. Sign up and read the free
notes on BXLT at:
https://www.erionline.net/BXLT.pdf
On Monday, shares in Opko Health Inc. recorded a trading volume
of 6.28 million shares, higher than their three months average
volume of 5.21 million shares. The stock ended the day 5.15% lower
at $9.94. Opko Health Inc.'s stock
has plummeted 19.71% in the last one month, 36.04% in the previous
three months and 0.50% on YTD basis. The company is trading below
its 50-day and 200-day moving averages by 26.31% and 27.13%,
respectively. Furthermore, shares of Opko Health Inc. have an RSI
of 30.05. The complimentary notes on OPK can be downloaded in PDF
format at:
https://www.erionline.net/OPK.pdf
Spectrum Pharmaceuticals Inc.'s stock edged 0.87% lower, to
close Monday's session at $6.81. The
stock recorded a trading volume of 1.56 million shares, above its
three months average volume of 1.17 million shares. Over the
previous three months and since the beginning of 2015, Spectrum
Pharmaceuticals Inc.'s shares have lost 7.60% and 1.73%,
respectively. However, the stock has gained 0.44% in the last one
month. The company is trading 1.70% above its 200-day moving
average. Furthermore, Spectrum Pharmaceuticals Inc.'s stock has an
RSI of 49.67. Register for free on Equity Research Institute and
access the latest research on SPPI at:
https://www.erionline.net/SPPI.pdf
Arrowhead Research Corp.'s stock finished Monday's session 0.95%
higher at $7.41. A total of 2.51
million shares were traded, which was above its three months
average volume of 1.17 million shares. Over the last one month and
the previous three months, Arrowhead Research Corp.'s shares have
gained 33.51% and 3.78%, respectively. Additionally, the stock has
advanced 0.41% since the beginning of 2015. The company's shares
are trading above their 50-day and 200-day moving averages by
20.15% and 10.93%, respectively. Arrowhead Research Corp.'s stock
has an RSI of 67.95. The complete research on ARWR is available for
free at:
https://www.erionline.net/ARWR.pdf
On Monday, shares in Oncothyreon Inc. ended the session 10.34%
lower at $3.38. The stock reported a
trading volume of 1.25 million shares, above its three months
average volume of 1.15 million shares. Although, Oncothyreon Inc.'s
shares have declined 15.08% in the previous three months, it has
surged 12.67% in the last one month and 77.89% on YTD basis. The
company is trading 36.28% above its 200-day moving average.
Moreover, shares of Oncothyreon Inc. have an RSI of 49.10. Free
in-depth research on ONTY is available at:
https://www.erionline.net/ONTY.pdf
--
About Equity Research Institute:
Equity Research Institute ("ERI") produces regular sponsored and
non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ
and micro-cap stocks. ERI has two distinct and independent
departments. One department produces non-sponsored analyst
certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ERI has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the
"Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as
necessary, based on sound investment judgment and publicly
available information which is believed to be reliable. The
Reviewer and the Sponsor have not performed any independent
investigations or forensic audits to validate the information
herein. Unless otherwise noted, any content outside of this
document has no association with the Author, the Reviewer, or the
Sponsor (collectively referred to as the "Production Team") in any
way. The Production Team is compensated on a fixed monthly basis
and do not hold any positions of interest in any of the securities
mentioned herein.
NO WARRANTY
ERI, the Author, the Reviewer and the Sponsor (collectively
referred to as the "Publishers") are not responsible for any error
which may be occasioned at the time of printing of this document or
any error, mistake or shortcoming. No liability is accepted by the
Publishers whatsoever for any direct, indirect or consequential
loss arising from the use of this document. The Publishers
expressly disclaim any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance
placed on the information in this document. Additionally, the
Publishers do not (1) guarantee the accuracy, timeliness,
completeness or correct sequencing of the information, or (2)
warrant any results from use of the information. The included
information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ERI nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
http://www.erionline.net.
RESTRICTIONS
ERI is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.erionline.net